What is the diagnosis and appropriate outpatient treatment for a stable adult without recent antibiotic use or known resistance who presents with acute bacterial pyelonephritis?

Diagnosis and Treatment of Acute Pyelonephritis

Diagnosis

Diagnose acute pyelonephritis clinically when a patient presents with fever ≥38°C plus flank pain or costovertebral angle tenderness, confirmed by urinalysis showing pyuria and/or bacteriuria. 1, 2

Clinical Presentation

• Fever ≥38°C with chills is present in nearly all patients, though it may be absent in up to 20% of elderly, diabetic, or immunocompromised individuals 2
• Flank pain or costovertebral angle tenderness is nearly universal; its absence should prompt consideration of alternative diagnoses 3, 2
• Lower urinary tract symptoms (dysuria, urgency, frequency) occur in approximately 80% of patients but may be completely absent in 20% 2
• In diabetic patients, up to 50% lack typical flank tenderness, making diagnosis more challenging 1, 2

Laboratory Evaluation

• Urinalysis showing pyuria and/or bacteriuria is the key diagnostic test 1, 2
• Urine culture with antimicrobial susceptibility testing must be obtained in all patients before initiating antibiotics 1, 4, 5
• Blood cultures should be reserved for patients who appear systemically ill, have high fever, are immunocompromised, or have an uncertain diagnosis 1, 6
• Escherichia coli accounts for >90% of cases in young, healthy women 2, 6

Imaging Recommendations

• Routine imaging is NOT indicated for initial evaluation of uncomplicated pyelonephritis 1, 2
• Obtain contrast-enhanced CT only if the patient remains febrile after 72 hours of appropriate antibiotics, experiences clinical deterioration, or belongs to a high-risk group (diabetic, immunocompromised, suspected obstruction or abscess) 1, 2
• Approximately 95% of patients become afebrile within 48 hours and nearly 100% within 72 hours of appropriate therapy 1, 4

---

Outpatient Treatment (Uncomplicated Pyelonephritis)

For stable, non-pregnant adults without recent antibiotic use or known resistance, prescribe oral ciprofloxacin 500 mg twice daily for 7 days as first-line therapy when local fluoroquinolone resistance is <10%. 1, 4, 7

First-Line Oral Regimens

When local fluoroquinolone resistance is <10%:

• Ciprofloxacin 500–750 mg orally twice daily for 7 days (clinical cure 96%, microbiological cure 99%) 1, 4
• Levofloxacin 750 mg orally once daily for 5 days (equivalent efficacy to ciprofloxacin) 1, 4, 7

When local fluoroquinolone resistance is ≥10%:

• Give one dose of ceftriaxone 1 g IV or IM, then start oral fluoroquinolone for 5–7 days 1, 4, 3
• Alternatively, give gentamicin 5–7 mg/kg IV/IM once, then oral fluoroquinolone 4

Second-Line Oral Regimen

• Trimethoprim-sulfamethoxazole 160/800 mg orally twice daily for 14 days ONLY if the organism is proven susceptible on culture (clinical cure 83%, inferior to fluoroquinolones) 1, 4, 3
• Do NOT use empirically due to high resistance rates (often >20%) 1, 4

Third-Line Oral Regimen (Avoid if Possible)

Oral β-lactams are significantly inferior (cure rates only 58–60% vs. 96% with fluoroquinolones) and should be avoided unless no other option exists 4

• If an oral β-lactam must be used, give ceftriaxone 1 g IV/IM first, then:
  • Amoxicillin-clavulanate 500/125 mg twice daily for 10–14 days, OR 4
  • Cefpodoxime 200 mg twice daily for 10–14 days, OR 4
  • Ceftibuten 400 mg once daily for 10 days 4

Agents to Avoid for Pyelonephritis

• Nitrofurantoin, oral fosfomycin, and pivmecillinam should NOT be used due to insufficient efficacy data 1, 4

---

Inpatient Treatment Indications

Hospitalize patients with any of the following:

• Sepsis or hemodynamic instability 1, 5
• Persistent vomiting or inability to tolerate oral medications 1, 6, 8
• Immunocompromised status (transplant, HIV, chronic steroids) 1, 4
• Diabetes mellitus (higher risk of abscess and emphysematous pyelonephritis) 1, 4
• Complicated pyelonephritis (obstruction, stones, anatomic abnormalities, abscess) 1, 8
• Pregnancy 1, 5
• Failed outpatient therapy 6, 8
• Suspected multidrug-resistant organisms 1, 5

Inpatient IV Antibiotic Regimens

Initial parenteral therapy options (choose based on local resistance patterns):

• Ciprofloxacin 400 mg IV twice daily 1, 4
• Levofloxacin 750 mg IV once daily 1, 4
• Ceftriaxone 1–2 g IV once daily (preferred broad-spectrum option) 1, 4
• Cefepime 1–2 g IV twice daily 1, 4
• Piperacillin-tazobactam 2.5–4.5 g IV three times daily 1, 4
• Gentamicin 5 mg/kg IV once daily (with or without ampicillin; not as monotherapy) 1, 4
• Meropenem 1 g IV three times daily (for suspected multidrug-resistant organisms) 1, 4

Transition to oral therapy once the patient is afebrile for 24–48 hours and can tolerate oral intake, using culture-directed agents 1, 4

---

Treatment Duration

• Fluoroquinolones: 5–7 days 1, 4
• Trimethoprim-sulfamethoxazole: 14 days 1, 4
• Oral or IV β-lactams: 10–14 days 1, 4

---

Follow-Up and Monitoring

• Reassess within 48–72 hours to ensure clinical improvement 1, 5
• If fever persists beyond 72 hours, obtain contrast-enhanced CT to evaluate for abscess, obstruction, or emphysematous changes 1, 2
• Repeat urine culture 1–2 weeks after completion of therapy 6
• Adjust antibiotics based on culture and susceptibility results once available 1, 4, 5

---

Critical Pitfalls to Avoid

• Do NOT use oral β-lactams as monotherapy without an initial IV ceftriaxone 1 g dose (cure rates only 58–60%) 4
• Do NOT use fluoroquinolones empirically in regions with >10% resistance without an initial parenteral dose 1, 4, 3
• Do NOT start trimethoprim-sulfamethoxazole empirically without culture confirmation or an initial parenteral dose 4
• Do NOT obtain imaging in uncomplicated cases responding to therapy within 48–72 hours 1, 2
• Do NOT delay imaging beyond 72 hours in patients with persistent fever, as this can miss abscess or obstruction 1
• Do NOT assume diabetic patients will have flank tenderness; 50% present atypically 1, 2
• Do NOT treat β-lactam regimens for fewer than 10 days, as shorter courses increase recurrence risk 4